title: Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
abstract: Germ-line mutations in the KIT receptor tyrosine kinase gene have been described in families with a propensity to develop gastrointestinal stromal tumor (GIST). There is limited information from large kindreds regarding median age at diagnosis, detailed histopathology, clinical effects of imatinib therapy and chromosomal abnormalities of the KIT gene. We identified a large kindred with GIST. Each family member was interviewed and appropriate medical records and radiographic imaging were obtained. Archival tumor tissue was obtained to confirm diagnosis, extract genomic DNA and perform fluorescent in situ hybridization cytogenetics of the KIT gene. Fifteen of 79 individuals with GIST were identified in this kindred. There were 8 males, the mean age at diagnosis was 53.9 (range 45-71) years. Histopathology revealed microscopic proliferation and nodularity in the myenteric plexus, spindled morphology, diffuse Kit but variable CD34 staining and low mitotic rates in the setting of metastatic disease. A deletion of codon 579 in exon 11 of the KIT gene was identified in tumor and normal tissue of this family. Mutation and cytogenetic analysis revealed homozygous loss of the wild-type KIT sequence in tumor from one individual. Four of 4 individuals treated with imatinib are alive and without progression while 9 of 11 individuals not treated with imatinib are deceased. This study describes a kindred with a propensity to develop GIST in an autosomal dominant pattern. Germ-line deletion of KIT codon 579 in GIST is associated with clinical benefit from imatinib, limited utility of mitoses to predict malignant potential, and a novel homozygous deletion of this codon in one individual.
authors.affiliation: Department of Sarcoma Medical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Kleinbaum
authors.forename: Alexander J F
authors.initials: AJ
authors.lastname: Lazar
authors.forename: Elena
authors.initials: E
authors.lastname: Tamborini
authors.forename: John C
authors.initials: JC
authors.lastname: Mcauliffe
authors.forename: Pamela B
authors.initials: PB
authors.lastname: Sylvestre
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Sunnenberg
authors.forename: Louise
authors.initials: L
authors.lastname: Strong
authors.forename: Lei L
authors.initials: LL
authors.lastname: Chen
authors.forename: Haesun
authors.initials: H
authors.lastname: Choi
authors.forename: Robert S
authors.initials: RS
authors.lastname: Benjamin
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Trent
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha